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Abstract: In most species, large variations in body size necessitate dose adjustments 
based on an allometric function of body weight. Despite the substantial disparity in body 
size between Miniature Horses and light-breed horses, there are no studies investigating 
appropriate dosing of any veterinary drug in Miniature Horses. The purpose of this study 
was primarily to develop a basis for pharmacologic scaling in the horse, and to determine 
the scaling exponents with which flunixin meglumine and gentamicin relate to body 
weight in the horse. A secondary purpose was to evaluate the current status of the 
therapeutic monitoring of gentamicin in the United States and Canada. To investigate 
pharmacologic scaling, a standard dose of flunixin meglumine was administered 
intravenously to eight Miniature Horses and eight Quarter Horses, and three-
compartmental analysis was used to compare pharmacokinetic parameters between breed 
groups. The total body clearance of flunixin was 0.97±0.30 mL⋅min-1⋅kg-1 in Miniature 
Horses and 1.04±0.27 mL⋅min-1⋅kg-1 in Quarter Horses. Similarly, a standard dose of 
gentamicin was administered intravenously to eight Miniature Horses and eight Quarter 
Horses, and three-compartmental analysis was used to compare pharmacokinetic 
parameters between breeds. The total body clearance of gentamicin components C1a, C2, 
C1, and summed components was 0.68±0.15 mL⋅min-1⋅kg-1, 0.69±0.16 mL⋅min-1⋅kg-1, 
0.72±0.17 mL⋅min-1⋅kg-1, and 0.71±0.16 mL⋅min-1⋅kg-1 respectively in Miniature Horses 
and 0.59±0.10 mL⋅min-1⋅kg-1, 0.61±0.09 mL⋅min-1⋅kg-1, 0.62±0.10 mL⋅min-1⋅kg-1, and 
0.62±0.09 mL⋅min-1⋅kg-1 respectively in Quarter Horses. There were no significant 
differences between Miniature Horses and Quarter Horses in clinically significant 
pharmacokinetic parameters (P>0.05) for either flunixin meglumine or gentamicin. An 
email-based survey disseminated to each of the veterinary teaching hospitals in the 
United States and Canada revealed that 42% of respondents currently perform therapeutic 
drug monitoring of aminoglycosides, with an average of 3.9 samples annually. The 
majority of veterinary TDM is performed in equine medicine. The fact that TDM is 
performed infrequently in veterinary teaching hospitals is at odds with the importance of 
TDM for aminoglycosides as demonstrated in human medicine. In conclusion, both 
flunixin meglumine and gentamicin may be administered to Miniature Horses at the same 
dose rates used typically in light-breed horses, with similar recommendations for TDM of 
gentamicin. 
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CHAPTER I 
 
 
INTRODUCTION 
 
When considerable variation in body weight exists among animals of the same or different 
species, physiological parameters such as metabolic rate, hepatic blood flow, glomerular filtration 
rate, and body surface area can all be described as a nonproportional, or allometric, function of 
body weight (Prothero, 1982; Prothero, 1984). Pharmacokinetic parameters rely on these 
physiological values, and therefore drug dosages also scale allometrically with body weight 
(Mordenti, 1986; Ritschel et al., 1992). The majority of descriptions of this phenomenon are 
interspecific, or between species, as the allometric relationships are used to make 
pharmacological dosage predictions across species and in humans from animal models 
(Mahmood et al., 2006; Huh et al., 2011). In general, smaller individuals have a higher surface 
area to volume ratio and a higher mass-specific metabolic rate. Therefore, faster drug clearance 
and shorter elimination half-life occur in smaller-sized individuals, necessitating higher drug 
doses on a body weight-normalized, or mg/kg basis, as compared to larger-sized individuals 
(Mordenti, 1986; Maxwell & Jacobson, 2008). When large variation exists in body weight among 
adults intraspecifically, or within a single species, allometric scaling within the species becomes 
important for the development of drug dosages (Maxwell & Jacobson, 2008; Martinez et al., 
2009). 
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Within the equine species, significant variation in body weight exists. Between the smallest 100 
kg Miniature Horse and the largest 1000 kg Percheron, there is a difference of about one order of 
magnitude. There have been no studies investigating a possible influence of allometry on 
pharmacokinetics within the equine species. Since pharmacokinetic studies are routinely 
performed in light-breed horses, current dosage recommendations for Miniature Horses may not 
be accurate if there is an allometric effect within the species. Miniature Horses exhibit unique 
medical predilections such as an increased propensity for fecalith obstructions (Haupt et al., 
2008), tracheal collapse (Aleman et al., 2008), lateral patellar luxation, (Engelbert et al., 1993) 
and hypertriglyceridemia (Waitt & Cebra, 2009). Despite the increasing popularity of the 
Miniature Horse breed over the last thirty years that led to the aforementioned publications, to the 
author’s knowledge there have been no studies that evaluate appropriate drug dosing in Miniature 
Horses. 
There is a perception by both horse owners and veterinarians, based on anecdotal reports, that 
Miniature Horses are more likely to experience toxicity from nonsteroidal anti-inflammatory 
drugs (NSAIDs) than are light-breed horses (Mogg, 2012). Flunixin meglumine is one of the most 
common NSAIDs prescribed in equine practice, and potential toxicities associated with it include 
right dorsal colitis, oral and gastric ulceration, and nephrotoxicity (Black, 1986; McConnico et 
al., 2008; Videla & Andrews, 2009). It is therefore crucial to determine if dose recommendations 
for this drug in Miniature Horses are both efficacious and pose a minimal risk of toxicity. 
Antibiotics are considered to have fairly straightforward scaling properties, because their efficacy 
is well correlated to their plasma concentration (Riviere et al., 1997). Specifically, gentamicin is 
an antibiotic that is eliminated unchanged through glomerular filtration, which depends directly 
on glomerular filtration rate and is likely to scale allometrically (Riviere et al., 1997). Gentamicin 
is a commonly used antibiotic in equine practice, and is potentially nephrotoxic. It is therefore 
both an important drug for which to improve dosage recommendations in Miniature Horses, and a 
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likely drug to enable the demonstration of allometry within the equine species. To improve the 
therapeutic efficacy and minimize the toxicity of aminoglycosides such as gentamicin, therapeutic 
drug monitoring (TDM) has become standard clinical practice in human medicine (Roberts et al., 
2012). In general, commercially available immunoassays have been the most appropriate for 
routine TDM of aminoglycosides in clinical laboratories because they are relatively accurate, 
precise, rapid, and simple to use (Stead, 2000; Dasgupta, 2012). There is very little information 
available about the current use and availability of TDM for aminoglycoside therapy in veterinary 
medicine. 
The purpose of the present study was primarily to develop a basis for pharmacokinetic scaling in 
the horse, and to determine the scaling exponents with which flunixin meglumine and gentamicin 
relate to body weight in the horse. A secondary purpose was to evaluate the current status of the 
therapeutic monitoring of gentamicin in the United States and Canada. If the disposition of 
flunixin meglumine and gentamicin were indeed nonproportional, or allometric, among horses of 
greatly different body weights, the administration of these drugs to Miniature Horses could be 
made safer and more effective by the determination of the appropriate dosage regimen for the 
breed. 
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CHAPTER II 
 
 
EFFECT OF BODY WEIGHT ON THE PHARMACOKINETICS OF FLUNIXIN 
MEGLUMINE IN MINIATURE HORSES AND QUARTER HORSES 
 
Introduction 
The Miniature Horse breed has increased in popularity over the last thirty years. There have been 
multiple recent publications demonstrating the unique medical predilections of the breed, 
including an increased propensity for fecalith obstructions (Haupt et al., 2008), tracheal collapse 
(Aleman et al., 2008), lateral patellar luxation (Engelbert et al., 1993), and hypertriglyceridemia 
(Waitt & Cebra, 2009). Despite these developments, to the authors’ knowledge there have been 
no studies evaluating appropriate drug dosing in Miniature Horses. 
The large difference in body size between Miniature Horses and standard-sized horses suggests 
the need to take body size into account when dosing Miniature Horses. When there is 
considerable variation in body size among animals of the same (Maxwell & Jacobson, 2008; 
Martinez et al., 2009) or different species (Mahmood et al., 2006; Huh et al., 2011), 
pharmacokinetic parameters such as clearance and elimination half-life relate to body weight in a 
nonproportional manner (Mordenti, 1986; Ritschel et al., 1992). In general, smaller individuals 
have a higher surface area to volume ratio and a higher mass-specific metabolic rate. As a 
consequence, faster drug clearance and shorter elimination half-lives occur in smaller-sized 
individuals, necessitating higher drug doses on a body weight normalized, or mg/kg basis, as
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compared to larger-sized individuals (Mordenti, 1986; Maxwell & Jacobson, 2008). This 
phenomenon is perhaps best recognized in the dosing of cytotoxic anticancer drugs, which is 
based on the nonproportional relationship between body surface area and body weight (Frazier & 
Price, 1998; Sparreboom, 2005; Loos et al., 2006). However, nonproportional drug disposition is 
also observed in numerous drug classes aside from anticancer drugs. Within the Equus genus, the 
clearance of phenylbutazone is much faster in miniature donkeys than is reported in standard 
donkeys (Matthews et al., 2001). Additionally, the clearance of phenolsulfonphthalein is faster in 
ponies than in light-breed horses (Hinchcliff et al., 1987). To the author’s knowledge, there have 
been no studies comparing the disposition of any drug among the weight categories of the horse. 
If drug disposition is nonproportional among horses of greatly different body weights, then 
therapeutic regimens in horses could be made safer and more effective by better defining the 
relationship between body size and drug disposition. 
Flunixin meglumine is a nonsteroidal anti-inflammatory drug used commonly in equine practice. 
In a recent survey of the American Association of Equine Practitioner member veterinarians, 91% 
of respondents prescribe it at least weekly (Hubbell et al., 2010). In addition to its use as a pain 
reliever, it is also used to inhibit the systemic effects of endotoxemia (Bryant et al., 2003). 
Potential toxicities associated with nonsteroidal anti-inflammatory drugs include right dorsal 
colitis, oral and gastric ulceration, and nephrotoxicity (Black, 1986; McConnico et al., 2008; 
Videla & Andrews, 2009). Because of these factors, it is important to ensure that dose 
recommendations for this drug are both efficacious and pose a minimal risk of toxicity. 
The purpose of the present study was to determine whether Miniature Horses should receive a 
different dose rate of flunixin meglumine than that used typically in light-breed horses, and in so 
doing, form a basis for future studies addressing dose recommendations in the Miniature Horse. 
The study hypothesis was that the total body clearance of flunixin would be faster in Miniature 
Horses as compared to Quarter Horses. 
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Materials and methods 
Horses 
Sixteen clinically healthy horses, consisting of Quarter Horse type horses (n = 8) and Miniature 
Horses (n = 8), were used in this study. Horses in each breed group were similar with respect to 
gender, age, and body condition score, but body weights were approximately five fold different 
between the two groups (Table 1). Horses were determined to be healthy by physical examination 
by a veterinarian, and a veterinarian assessed body condition score of each horse, using a nine 
point system (Henneke et al., 1983). Horses were housed in their usual environment or in 
individual stalls with free access to water and hay during the study. The study protocol was 
approved by the Oklahoma State University Animal Care and Use Committee and written 
informed consent was obtained for the four Quarter Horses and eight Miniature Horses that were 
privately owned. The remaining four Quarter Horses were maintained as part of a University 
owned teaching herd. 
Table 1. Summary of demographic data for horses employed in the present study.  
  Quarter Horses Miniature Horses P value 
Age (yr) 7 (3-12) 6 (3-12) 0.63 
Weight (kg) 489 (420-559) 100 (82-126) <0.001 
Body Condition Score 5.7 (5.3-6.3) 5.5 (4.7-6.7) 0.50 
Gender   1.0 
     Gelding 4 4  
     Mare 4 4  
Data are expressed as the mean, followed by the range. 
 
Drug administration 
A commercial formulation of flunixin meglumine (Flunixiject; Butler Schein Animal Health, 
Dublin, Ohio, USA).was administered as an intravenous bolus via an indwelling 14 gauge 
catheter placed in the right jugular vein using an aseptic technique. A dose of approximately 1.1 
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mg·kg-1 was calculated for each horse such that an accurate volume could be measured using 
standard syringes. 
Blood collection 
Baseline plasma samples were collected from all horses prior to drug administration. Following 
intravenous administration of flunixin meglumine, 6 mL blood samples were collected via a 
separate 14 gauge catheter previously placed in the opposite jugular vein at 3, 6, 10, 20, and 40 
minutes, and at 1, 2, 3, 4, 6, 8, 10, 12 hours. Further sampling was performed by jugular 
venipuncture at 24 hours after the administration of flunixin. All samples were collected into 
heparinized blood collection tubes and placed immediately into an ice-water bath. Samples were 
then centrifuged within one hour of collection and plasma was separated and stored at -80 °C 
until assayed. 
Flunixin assay 
A novel assay utilizing high performance liquid chromatography (HPLC) with ultraviolet 
detection was developed for the sensitive and specific determination of plasma flunixin 
concentrations in equine plasma. The HPLC system consisted of a ProStarTM 210 pump, 410 
autosampler and 285 nm ultraviolet detector (Varian Medical Systems, Palo Alto, California, 
USA). A reversed-phase column and guard column (SymmetryTM C18, 5 µm, 4.6 x 150 mm; 
Waters Corporation, Milford, Massachusetts, USA) were utilized at 30 °C for analyte separation. 
Mobile phase components were prepared fresh daily and consisted of 1.5% acetic acid and 10% 
acetonitrile in water (mobile phase A) and 1.5% acetic acid and 90% acetonitrile in water (mobile 
phase B). Stock solutions were prepared by adding flunixin (Sigma-Aldrich, St. Louis, Missouri, 
USA) or the internal standard, niflumic acid (Sigma-Aldrich, St. Louis, Missouri, USA), to 
methanol. Plasma calibrants were prepared at concentrations of 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 
5, 10, 15, and 30 µg·mL-1 using flunixin stock solutions and heparinized plasma from 
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unmedicated horses. Calibrants and quality control samples were prepared by adding 950 µL of 
unmedicated equine heparinized plasma to 50 µL of the appropriate calibrant or quality control 
solution, followed by vortex mixing. Calibrant curves were constructed from the ratio of 
flunixin:niflumic acid and were weighted using the reciprocal of the flunixin concentration. 
Criteria for acceptance of each run included that a minimum of five calibrators back-calculated to 
within 15% of the nominal concentration and that the coefficient of determination was >0.99. All 
calibrators that met the acceptance criteria were included in the calibration curve associated with 
each run, and calibration samples always bracketed the experimentally determined flunixin 
concentrations. One milliliter of 2% phosphoric acid containing niflumic acid at a concentration 
of 4 µg·mL-1 was added to each 1 mL plasma sample and vortex mixed. Liquid-liquid extraction 
was performed via the addition of 10 mL of diethyl ether. End over end mixing for 15 minutes 
was followed by centrifuging for 10 minutes. The supernatant was aspirated and dried under 
nitrogen for 20 minutes at 30°C. The residue was dissolved in 200 µL of mobile phase and 50 µL 
were injected onto the column. The mobile phase consisted of 60% “A” and 40% “B” with 
isocratic flow at 1 mL·min-1. Flunixin eluted at approximately 10 minutes, and niflumic acid at 
approximately 20.5 minutes. Recovery estimates were performed in plasma using six replicates. 
Intraday accuracy and coefficient of variation estimates were performed in plasma using three 
replicates. Interday accuracy and coefficient of variation estimates were performed in plasma 
using three replicates on three separate days. The limit of quantification was estimated using six 
replicates and was defined as the lowest concentration associated with a tenfold signal:noise ratio. 
The limit of detection was estimated using three replicates and was defined as the concentration 
at which signal:noise was at least three fold. 
Pharmacokinetic analysis 
Plasma flunixin concentrations following intravenous administration of flunixin meglumine were 
analyzed compartmentally using Thermo Kinetica software version 5.0 (Thermo Fisher Scientific, 
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Philadelphia, Pennsylvania, USA). Intravenous data for each horse were fit to the following 
equation: 
C = Ai ⋅e−α⋅t
i=1
n
∑  
Data were weighted by the reciprocal of the plasma flunixin concentration and were fit to 
standard compartmental models. The most appropriate model was selected using Aikaike’s 
information criterion and the Schwarz criterion, and standard compartmental equations were then 
used to estimate the pharmacokinetic parameters for each horse. The mean and standard deviation 
for each group (Miniature Horses and Quarter Horses) was estimated for each pharmacokinetic 
parameter.  
Allometric comparisons 
The total body clearance for flunixin determined in Miniature Horses was compared to that 
predicted by standard allometry, as has been reported previously (Mordenti, 1986). The general 
form of the allometric equation used for scaling of pharmacokinetic parameters was: 
y = a ⋅ BWb, 
where y is flunixin clearance; BW is the body weight;  a is the allometric coefficient, and b is the 
allometric exponent. The allometrically predicted flunixin clearance in Miniature Horses was 
calculated from the Quarter Horse clearance data by solving for the mass coefficient in the 
equation above and setting b = 0.75, as is frequently used in standard allometric calculations and 
is arguably a universal scaling exponent across species (Hu & Hayton, 2001). The values of log10 
total body clearance were regressed against log10 body weight and compared to the curve 
predicted by standard allometry. 
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Statistical analysis 
A Wilcoxon rank-sum test was used to analyze the difference in body condition score between 
the groups, whereas a two-sample t-test was used to test whether age differed between Quarter 
Horses and Miniature Horses. Two sample Student’s t tests were used to test the difference in 
selected pharmacokinetic parameters: mass normalized clearance (Cl), elimination phase rate 
constant (γ), area under the plasma concentration versus time curve (AUC), apparent volume of 
distribution at steady state (Vdss), and volume of the central compartment (Vc).. Significance was 
set at α = 0.05. Statistical calculations were performed using SigmaPlot software version 11.0 
(Systat Software, Inc., Chicago, Illinois, USA). 
 
Results 
Assay 
At fortified plasma flunixin concentrations of 0.075 µg·mL-1, 5 µg·mL-1, and 12.5 µg·mL-1, 
recovery of flunixin was 86 ± 5%, 86 ± 2%, and 85 ± 3%, respectively. At a plasma concentration 
of 4.0 µg·mL-1, recovery of niflumic acid was similar to that of flunixin at 83 ± 3%. Intraday 
accuracy of the assay  at 0.075 µg·mL-1, 3.75 µg·mL-1 and 12.5 µg·mL-1 was 99%, 93%, and 
92%, respectively. Intraday coefficient of variation at 0.075 µg·mL-1, 3.75 µg·mL-1, and 12.5 
µg·mL-1 was 1%, 2%, and 2%, respectively. Interday accuracy at 0.075 µg·mL-1, 3.75 µg·mL-1 
and 12.5 µg·mL-1 was 99%, 96%, and 91%, respectively. Interday coefficient of variation at 
0.075 µg·mL-1, 3.75 µg·mL-1, and 12.5 µg·mL-1 was 3%, 2%, and 1%, respectively. The limit of 
quantification, 0.025 µg·mL-1, was associated with good accuracy and precision, with an accuracy 
of 93% and a coefficient of variation of 11%. The limit of detection was 0.00625 µg·mL-1. The 
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assay provided good separation of flunixin and the internal standard from endogenous plasma 
constituents, even at low plasma flunixin concentrations (Figure 1).  
 
 
Figure 1: Chromatograms of unmedicated equine plasma (grey line) and equine plasma with an 
estimated flunixin concentration of 0.15 µg/mL (black line), sampled at 12 hours after 
administration of flunixin meglumine. Peaks: IS = internal standard. 
 
Quantification of flunixin 
All horses tolerated the administration of a single dose of flunixin meglumine well, with no 
adverse effects noted for the duration of the study. In addition to sampling times described above, 
additional sampling was performed at 36 hours in the first three Quarter Horses and the first three 
Miniature Horses studied, but flunixin could not be detected in any of these six samples. 
Thereafter, collection of the 36 hour post-administration sample was discontinued. Flunixin 
concentrations rapidly declined after intravenous administration, followed by a slower 
distribution phase, and then an extended elimination phase; flunixin could be quantified for at 
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least 12 hours in all horses and for 24 hours in 5/8 Quarter Horses and 4/8 Miniature Horses 
(Figure 2).  
 
Figure 2: Mean (± s.e.m.) plasma concentrations of flunixin after i.v. administration of flunixin 
meglumine at a dose rate of 1.1 mg/kg to eight Miniature Horses and eight Quarter Horses. 
Flunixin concentrations were similar between the two groups throughout the sampling period. 
 
Pharmacokinetics 
The most appropriate compartmental model for pharmacokinetic analysis was determined to be a 
three compartment model in all horses (Table 2). There were no significant differences between 
groups in clearance (P = 0.66), elimination phase rate constant (P = 0.44), AUC (P = 0.51), Vdss 
(P = 0.89), or the Vc (P = 0.49). In addition, the mass specific clearance of flunixin was not 
related to body weight (Figure 3a).  
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Table 2. Comparison of pharmacokinetic parameters for flunixin after i.v. administration to 
Quarter Horses and Miniature Horses.  
Parameter Quarter Horses Miniature Horses 
Dose (mg·kg bwt-1) 1.10 ± 0.02 (1.07-1.14) 1.11 ± 0.02 (1.08-1.13) 
C0 (µg·mL-1) 19.8 ± 2.7 (17.3-25.2) 19.1 ± 3.4 (14.7-23.1) 
A (µg·mL-1) 9.9 ± 2.1 (7.4-13.5) 9.7 ± 1.9 (7.5-12.2) 
B (µg·mL-1) 8.3 ± 0.8 (7.2-9.5) 6.6 ± 1.1 (4.7-7.7) 
C (µg·mL-1) 1.6 ± 1.1 (0.5-3.5) 2.8 ± 2.3 (0.4-8.2) 
t1/2α (h) 0.07 ± 0.01 (0.05-0.08) 0.08 ± 0.02 (0.05-0.10) 
t1/2β (h) 0.81 ± 0.18 (0.57-1.11) 0.79 ± 0.21 (0.53-1.13) 
t1/2γ (h) 3.38 ± 1.14 (2.06-6.03) 2.96 ± 1.00 (2.14-5.98) 
t1/2k10 (h) 0.62 ± 0.16 (0.47-1.17) 0.70 ± 0.22 (0.47-1.45) 
k10 (hr-1) 1.1 ± 0.3 (0.6-1.5) 1.0 ± 0.3 (0.5-1.5) 
k12 (hr-1) 3.9 ± 0.7 (3.3-5.5) 3.5 ± 1.1 (2.7-6.2) 
k21 (hr-1) 5.3 ± 0.6 (4.6-6.6) 4.7 ± 1.2 (3.6-6.9) 
k13 (hr-1) 0.3 ± 0.1 (0.2-0.5) 0.3 ± 0.1 (0.2-0.4) 
k31 (hr-1) 0.3 ± 0.1 (0.1-0.6) 0.4 ± 0.2 (0.1-0.9) 
Vc (L·kg bwt-1) 0.056 ± 0.007 (0.042-0.063) 0.059 ± 0.011 (0.048-0.074) 
Vd(ss) (L·kg bwt-1) 0.157 ± 0.022 (0.119-0.183) 0.159 ± 0.039 (0.095-0.216) 
Vd(area) (L·kg bwt-1) 0.324 ± 0.104 (0.182-0.507) 0.279 ± 0.149 (0.111-0.621) 
Cl (mL·min-1·kg bwt-1) 1.04 ± 0.27 (0.60-1.48) 0.97 ± 0.30 (0.47-1.20) 
AUC (µg·h·mL-1) 18.8 ± 5.5 (12.4-30.8) 21.3 ± 9.2 (14.0-39.6) 
MRT (hr) 2.7 ± 0.7 (1.8-3.7) 3.0 ± 1.3 (1.7-5.9) 
Values are expressed as mean or *harmonic mean ± s.d. (range)[37]. Dose = dose administered; 
C0 = serum drug concentration at time 0; A = coefficient of rapid distribution phase; B = coefficient 
of slow distribution phase; C = coefficient of elimination phase; t1/2α = rapid distributional half-life; 
t1/2β= slow distributional half-life; t1/2γ = terminal elimination phase half-life; t1/2k10 = elimination 
half-life; k
10
 = first-order rate constant for elimination from the central compartment; other 
intercompartmental rate constants follow similar nomenclature; Vc = apparent volume of the 
central compartment; Vd(ss) = apparent volume of distribution at steady state; Vd(area) = apparent 
14	  
	  
volume of distribution by area; Cl = total body clearance; AUC = Area under the plasma 
concentration versus time curve, extrapolated to infinity; MRT = mean residence time 
 
Allometric comparison 
The regression curve relating measured total body clearance to body weight was associated with a 
mass exponent of approximately unity: 
 CL = 0.046 ⋅ BW1.04, R2 = 0.88 
The 95% confidence interval (0.82, 1.26) for the calculated mass exponent did not contain the ¾ 
exponent predicted by the principles of standard allometry (Figure 3b). If the clearance of 
flunixin in Miniature Horses had varied allometrically from that of Quarter Horses by the ¾ mass 
exponent, then the predicted flunixin clearance in the Miniature Horses would have been 1.56 
mL·min-1·kg bwt-1, more than 50% greater than the measured clearance of 0.97 mL·min-1·kg bwt-
1. The statistical power (β) of the present study to detect such a difference was 0.95, with s.d. = 
0.27 and α  = 0.05. The other pharmacokinetic parameters tested, including the elimination rate, 
AUC, Vdss and Vc, were similarly unrelated to body weight (elimination rate and AUC) or were 
directly proportional to body weight (Vdss, Vc; data not shown). 
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Figure 3: Relationship between flunixin clearance and body weight.. a) Mass specific clearance 
of flunixin versus body weight in Miniature Horses and Quarter Horses, demonstrating that total 
body clearance was similar between the two groups when normalized to body weight. b) Total 
body clearance of flunixin versus body weight in Miniature Horses and Quarter Horses, showing 
that total body clearance varied proportionally with body weight. The regression line calculated 
from the data (solid line) is compared to that predicted from standard allometry (dashed line). 
 
Discussion 
The novel flunixin assay employed in the present study allowed the sensitive and specific 
determination of flunixin concentrations in equine plasma. The sensitivity of this method was 
improved as compared with previously reported HPLC methods, with the limit of detection of 
0.00625 µg·mL-1 lower than previous reports of 0.05 µg·mL-1 (Semrad et al., 1985; Higgins et al., 
1987) and the limit of quantification of 0.025 µg·mL-1 lower than previous reports of 0.05 µg·mL-
1 (Soma et al., 1988). Although the two compartment model describing flunixin pharmacokinetics 
in horses predominates in the literature (Chay et al., 1982; Semrad et al., 1985; Lees et al., 1987; 
Soma et al., 1988), the sensitivity of the present study allowed for the first time the reliable 
quantification of flunixin for up to 24 hours after administration. The longer detection time 
demonstrated the presence of a third compartment, which was confirmed by the Akaike 
information criterion and the Schwarz criterion in all horses. The stated accuracy, precision, and 
recovery of the novel assay were also well within acceptable limits. As this was the first 
description of this specific method for analysis of flunixin in equine plasma, the method was 
deemed robust and feasible for future pharmacokinetic studies. 
The pharmacokinetic parameters calculated in the present study for light-breed horses were 
similar when compared to those in previous studies (Lees et al., 1987; Coakley et al., 1999). 
Specifically, the calculated mass specific clearance of flunixin in light-breed horses of 1.04 ± 
0.27 mL·min-1·kg bwt-1 was very similar to the clearance of 1.1 ± 0.2 mL·min-1·kg bwt-1 (Coakley 
et al., 1999) reported previously in light-breed horses given the same dose of flunixin. Low 
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variability in the kinetics of flunixin was observed among horses in the present study, 
demonstrating that flunixin pharmacokinetics are generally predictable, even within these two 
disparate breeds of horses. 
An acknowledged shortcoming of this study was the lack of any samples taken between the 12 
hour and 24 hour time points. The study was designed in this fashion to encourage the 
participation of privately owned horses. The inclusion of 16 hour and 20 hour post-administration 
samples would have improved the definition of the third compartment. To investigate the 
possibility that sampling times affected the calculation of the key parameters under investigation, 
the pharmacokinetic analysis was repeated on the plasma flunixin versus time data truncated at 
the 12 hour time point, when all horses had quantifiable plasma flunixin concentrations. The 
elimination rate constant was not substantially affected by this truncated analysis, and the 
significance of the comparisons did not change. For example, the terminal phase elimination rates 
in Quarter Horses and Miniature Horses with inclusion of quantifiable 24 hour time points were 
0.20 hr-1 and 0.23 hr-1, respectively. When the data were truncated at 12 hours, the terminal phase 
elimination rates in Quarter Horses and Miniature Horses were 0.25 hr-1 and 0.24 hr-1, 
respectively. Therefore, the selected sampling time points did not appear to play an important role 
in the outcome of the study. 
Physiological parameters such as metabolic rate, hepatic blood flow, glomerular filtration rate, 
and body surface area can all be described as a nonproportional, or allometric, function of body 
weight when there is a large amount of size variation (Prothero, 1982; Prothero, 1984). Because 
of this allometric relationship, pharmacokinetic parameters and therefore drug dosages also scale 
allometrically with body weight (Mordenti, 1986; Ritschel et al., 1992). This is described most 
extensively between species, or interspecifically (Mahmood et al., 2006; Huh et al., 2011). 
However, intraspecific allometric scaling, or allometry within a single species, becomes 
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important when there is considerable variation in body weight among adults within the species 
(Maxwell & Jacobson, 2008; Martinez et al., 2009).  
The large variation in body size within the equine species led the authors to hypothesize that 
flunixin would follow an allometric relationship in the horse, as has been reported for 
phenylbutazone clearance in mininature donkeys as compared to full-sized donkeys (Matthews et 
al., 2001). However, the results of the present study in Miniature Horses did not demonstrate a 
breed related effect on the disposition of flunixin. Statistical comparisons between breed groups 
were performed on those pharmacokinetic parameters used commonly in allometric calculations 
and deemed clinically relevant to dose calculations (Cox et al., 2004; Dinev, 2008; Gebru et al., 
2011). These key pharmacokinetic parameters for flunixin showed no significant differences 
between Miniature Horses and Quarter Horses. Furthermore, the present data did not support a 
non-proportional, or allometric, relationship between flunixin disposition and body weight in the 
horse.  
For species in which standard allometry is followed, drug clearance is proportional to body 
weight raised to the ¾ power on a double log10 plot (Figure 3b). The range in equine body 
weights utilized in the present study was sufficient to detect an allometric effect on flunixin 
clearance, if the horses had indeed followed standard allometry as we initially hypothesized. It 
was also possible that flunixin clearance followed a scaling factor other than the ¾ power, such as 
the 2/3 power commonly utilized in body surface area calculations (Gouma et al., 2012). 
Therefore, flunixin clearance was also plotted against body weight on a double log10 plot to 
examine the possibility of a nonproportional relationship. However, the mass exponent of that 
comparison was very similar to unity, further demonstrating the absence of any allometric effect. 
Other pharmacokinetic parameters (elimination rate, AUC, and volumes of distribution) that were 
subject to allometric effects in previous studies failed to vary non-proportionally with body 
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weight in the present study in horses. Therefore, the present data do not support adjustment of the 
dose rate of flunixin meglumine in Miniature Horses for pharmacokinetic reasons. 
Although the efficacy and toxicity of flunixin have not been compared between breeds, the 
pharmacokinetic/pharmacodynamic relationship of flunixin has been well described in the horse 
(Toutain et al., 1994; Landoni & Lees, 1995; Lees et al., 2004). An intravenous dose of 1 mg/kg 
was predicted to have near maximal effects for two to ten hours after administration on the 
pharmacodynamic endpoints of local skin temperature, stride length, rest angle flexion, maximal 
carpal flexion and circumference of the inflamed joint after induction of carpal osteoarthritis 
(Toutain et al., 1994). The majority of these effects were explained by drug concentration (Lees et 
al., 2004). Because the efficacy and toxicity of flunixin are dependent on its pharmacokinetic 
interactions, dosage recommendations for this drug in Miniature Horses can justifiably rely on the 
consistency of pharmacokinetic parameters without specifically comparing the 
pharmacodynamics of the drug between breeds. 
While the present results do not support a need to adjust the dose rate for flunixin administration 
to Miniature Horses, drugs that are subject to different routes of elimination might be subject to 
size effects on drug disposition. Flunixin is a highly protein bound drug that is metabolized in the 
liver but is not avidly extracted, characteristics that may be associated with poor correlation 
between body weight and drug clearance when compared across species (Riviere et al., 1997). 
Indeed, a compilation of interspecific allometric data from forty-four different drugs across 
multiple veterinary species reported that the elimination half-life of flunixin did not correlate with 
body weight, with a coefficient of determination of 0.40 (Riviere et al., 1997). In contrast, the 
same study reported that elimination half-life was significantly correlated with body weight in 
drugs cleared via glomerular filtration such as carbenicillin, tetracycline, cephapirin, apramycin, 
chlortetracycline, gentamicin, and ampicillin (Riviere et al., 1997). Future studies with these 
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drugs may be more likely to show allometric scaling within the equine species, and it is possible 
that they would require dose adjustments for use in Miniature Horses.  
There is a current perception by both horse owners and veterinarians that Miniature Horses are 
more likely to experience toxicity from nonsteroidal anti-inflammatory drugs (NSAIDs) than are 
light-breed horses (Mogg, 2012). Such evidence is primarily anecdotal, and likely represents 
overdosage of NSAIDs in Miniature Horses when their smaller body weight is not taken into 
account, a situation observed previously in a case referred to this institution (Lyndi Gilliam, 
personal communication). The absence of objective studies investigating the pharmacokinetics of 
any veterinary drug in Miniature Horses has required the veterinary practitioner to use only 
subjective information to support therapeutic decisions in this unique breed. Although it remains 
imperative to adjust drug doses to body weight when administering therapeutics to Miniature 
Horses, the results of the present study allow practitioners to more confidently administer flunixin 
meglumine to Miniature Horses using typical equine dosing regimens. 
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CHAPTER III 
 
 
EFFECT OF BODY WEIGHT ON THE PHARMACOKINETICS OF GENTAMICIN IN 
MINIATURE HORSES AND QUARTER HORSES 
 
Introduction: 
 Aminoglycosides are commonly administered in veterinary medicine due to their activity 
against many gram-negative bacteria. Gentamicin use is especially common in equine practice. In 
a survey of Diplomates of the American College of Veterinary Surgeons performing equine 
surgery at veterinary teaching hospitals in the United States, gentamicin was used routinely by 
84% of respondents along with potassium penicillin as a preoperative drug for colic surgery 
(Traub-Dargatz et al., 2002). Although it is frequently used, the potential nephrotoxicity of 
gentamicin is a concern (van der Harst et al., 2005). The current recommendation for gentamicin 
administration is once daily dosing, allowing higher therapeutic efficacy with no increase in 
nephrotoxicity due to the saturable nature of uptake by the renal tubular cells (Magdesian et al., 
1998; Turnidge, 2003). More recent studies have looked at using therapeutic drug monitoring to 
refine the dosing regimens for gentamicin, and it remains a current topic of research within the 
field of equine medicine (Read et al., 2011). 
Therapeutic drug monitoring (TDM) can be used to combine maximal antimicrobial efficacy with 
minimal toxicity, and this has become standard clinical practice in human medicine (Roberts
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 et al., 2012). A mathematical model taking both efficacy and toxicity into account showed that 
optimal aminoglycoside dosing requires a sophisticated system of TDM (Croes et al., 2012). With 
a once daily dosing regimen, it is recommended that trough concentration should be monitored to 
ensure levels below 2 µg/mL (Dasgupta, 2012). In general, commercially available 
immunoassays have been the most appropriate for routine TDM of aminoglycosides in clinical 
laboratories (Stead, 2000; Dasgupta, 2012). However, most immunoassay methods measure total 
gentamicin concentration in serum or plasma but do not measure the individual components 
within the gentamicin complex (Dasgupta, 2012). There is minimal information available about 
the current use of TDM for aminoglycosides in veterinary medicine, but a recent change in the 
availability of commonly used clinical equipment may have affected the routine monitoring of 
aminoglycosides in veterinary patients.  
When considering appropriate dose regimens for gentamicin within the equine species, the impact 
of allometry may be important to take into account. The concept of allometry is based on 
nonproportional changes in physiological parameters such as glomerular filtration rate, oxygen 
consumption, heart and respiratory rate, cardiac output, and basal metabolic rate with body 
weight when considered over a wide range in species (Prothero, 1982; Prothero, 1984). Because 
pharmacokinetic parameters and corresponding drug dosages are dependent upon physiologic 
functions, they may similarly vary in a nonproportional, or allometric, manner (Mordenti, 1986; 
Ritschel et al., 1992). Aminoglycosides in particular have been reported to scale allometrically 
between species (Riviere et al., 1997). The elimination of aminoglycosides such as gentamicin 
through glomerular filtration depends directly on glomerular filtration rate, which clearly scales 
allometrically across species (Kirkwood & Merriam, 1990; Riviere et al., 1997). 
When there is considerable variation in body weight among adults within a species, intraspecific 
allometric scaling, or allometry within a single species, becomes important (Maxwell & 
Jacobson, 2008; Martinez et al., 2009). The large difference in size between Miniature Horses and 
23	  
	  
standard-sized horses suggests the need to consider body size when developing dosage regimens 
for Miniature Horses. To date, there has only been one study investigating appropriate drug 
dosing in Miniature Horses (Lee & Maxwell, in progress). Although this study did not support a 
need to adjust the dose rate for flunixin administration to Miniature Horses beyond proportional 
adjustment for body weight, flunixin is a highly protein bound drug that is metabolized in the 
liver but is not avidly extracted, characteristics that make it less likely than gentamicin to follow 
an allometric relationship (Riviere et al., 2007). If the disposition of gentamicin is indeed 
nonproportional among horses of greatly differing body weights, then the administration of this 
drug could be made safer and more effective by better definition of the allometric effect of body 
size on drug disposition. 
The objectives of the present study were to evaluate the current status of the therapeutic drug 
monitoring of aminoglycosides in veterinary patients in the United States and Canada and to 
determine whether gentamicin disposition varies allometrically with body weight in Miniature 
Horses as compared to Quarter Horses.. 
 
Materials and methods: 
Therapeutic drug monitoring survey 
A survey on current practices in aminoglycoside TDM at North American veterinary teaching 
hospitals was sent electronically to list serves of the American College of Veterinary 
Pharmacology and Therapeutics and to the American Association of Veterinary Pharmacology 
and Therapeutics (Appendix A). The first question of the survey elicited information regarding 
which veterinary teaching hospital they worked for, and whether that hospital currently performs 
TDM of aminoglycosides. If the hospital was not currently performing TDM, the survey was 
terminated. The second part of the survey pertained to which assay and instrument was utilized 
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for TDM, whether the assay was performed in-house or off site, approximately how many 
samples were analyzed per year, and approximately what proportion of samples were from small 
animal patients as compared to large animal patients. The survey was subsequently approved by 
the Association of American Veterinary Medical Colleges and disseminated to pharmacologists, 
equine clinicians, or the administration  of each veterinary teaching hospital in the United States 
and Canada, if no response had been received from the electronic survey. 
Horses 
Sixteen clinically healthy horses, consisting of Quarter Horse type horses (n = 8) and Miniature 
Horses (n = 8), were used in this study. Horses in each breed group were similar with respect to 
gender, age, and body condition score, but body weights were approximately five fold different 
between the two groups (Table 3). Horses were determined to be healthy by physical examination 
by a veterinarian, and a veterinarian assessed body condition score of each horse, using a nine 
point system (Henneke et al., 1983). Horses were housed in their usual environment or in 
individual stalls with free access to water and hay during the study. The study protocol was 
approved by the Oklahoma State University Animal Care and Use Committee and written 
informed consent was obtained for the five Quarter Horses and eight Miniature Horses that were 
privately owned. The remaining three Quarter Horses were maintained as part of a University 
owned teaching herd. 
Table 3. Summary of demographic data for horses employed in the gentamicin study.  
  Quarter Horses Miniature Horses P value 
Age (yr) 9 (4-14) 7 (3-14) 0.50 
Weight (kg) 476 (420-527) 109 (70-141) <0.001 
Body Condition Score 5.3 (5.0-5.5) 5.6 (4.7-6.8) 0.25 
Gender   1.0 
     Gelding 4 4  
     Mare 4 4  
Data are expressed as the mean, followed by the range. 
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Drug administration 
A commercial formulation of gentamicin (Gentamicin sulfate; Sparhawk Laboratories, Lenexa, 
Kansas, USA) was administered as an intravenous bolus via an indwelling 14 gauge catheter 
placed using aseptic technique in the right jugular vein. A dose of approximately 6.6 mg·kg-1 of 
gentamicin was calculated for each horse and rounded to the nearest syringe increment for 
accurate calculation of the administered dose. 
Blood collection 
Baseline plasma samples were collected from all horses prior to drug administration. Following 
bolus intravenous administration of gentamicin, 10 mL blood samples were collected via a 
separate 14 gauge catheter previously placed in the left jugular vein at 3, 6, 10, 20, and 40 
minutes, and at 1, 1.5, 2.5, 4, 6, 8, 10, 12 hours. Further sampling was performed by jugular 
venipuncture at 24 hours after the administration of gentamicin. All samples were collected into 
heparinized blood collection tubes and placed immediately into an ice-water bath. Samples were 
then centrifuged within one hour of collection and plasma was separated and stored at -80 °C 
until assayed. 
Gentamicin assay 
A previously described high performance liquid chromatography (HPLC) assay was modified for 
the sensitive and specific determination of plasma gentamicin concentrations in equine plasma 
(Isoherranen and Soback 2000). The HPLC system consisted of a ProStarTM 210 pump, 410 
autosampler and ultraviolet detector (Varian Medical Systems, Palo Alto, California, USA). A 
reversed-phase column and guard column (SymmetryTM C18, 5 µm, 4.6 x 150 mm; Waters 
Corporation, Milford, Massachusetts, USA) were utilized at 25 °C for analyte separation. Mobile 
phase components were 8 mM Tris at pH = 7 (mobile phase A) and 50% acetonitrile and 50% 
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methanol (mobile phase B). The mobile phase consisted of 78% “A” and 22% “B” with gradient 
flow at 1.2 mL·min-1. Stock solutions were prepared by adding gentamicin components C1, C1a, 
or C2 (Toku-E, Bellingham, Washington, USA) or the internal standard, tobramycin (Sigma-
Aldrich, St. Louis, Missouri, USA), to water. Plasma calibrants were prepared at concentrations 
of 0.1, 0.2, 0.5, 1, 2, 5, 10, 20 µg·mL-1 using gentamicin component stock solutions and 
heparinized plasma from unmedicated horses. Calibrants and quality control samples were 
prepared by adding 970 µL of unmedicated equine heparinized plasma to 30 µL of the 
appropriate calibrant or quality control solution, followed by vortex mixing. Calibrant curves 
were constructed from the ratio of gentamicin:tobramycin for each component and were weighted 
using the reciprocal of the gentamicin concentration. Criteria for acceptance of each run included 
that a minimum of five calibrators back-calculated to within 15% of the nominal concentration 
and that the coefficient of determination was >0.99. Ten micrograms of tobramycin in 25 µL of 
water were added to each 1 mL calibrator, quality control, or experimental sample and vortex 
mixed. For protein precipitation and alkalization, 500 µL of 170mM Tris at pH = 12 and 2,000 
µL acetonitrile were added. After mixing and centrifugation, derivitization was performed by 
adding 200 µL of 1-fluoro-2,4-dinitrobenzene/ acetonitrile (20:80, v/v) to the supernatant and 
heating in a 80°C water bath for 60 minutes. Samples were then applied to a 500 mg C8 solid 
phase extraction cartridge (Bond-Elut, Agilent Technologies, Santa Clara, California). The 
cartridges were first conditioned with methanol and water. After application of the derivitized 
sample mixed with 1 mL 40% acetonitrile, cartridges were washed with 1 mL 10% methanol in 
10 mM Tris at pH = 10 and eluted with 2 mL acetonitrile. The eluent was dried under nitrogen for 
50 minutes at 40°C. The residue was dissolved in 500 µL of mobile phase and 50 µL were 
injected onto the column. Tobramycin eluted at approximately 5 minutes, gentamicin C1a at 
approximately 9.5 minutes, gentamicin C2 at approximately 11 minutes, and gentamicin C1 at 
approximately 12.5 minutes. Recovery estimates were performed in plasma using three replicates. 
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Intraday and interday accuracy and coefficient of variation were estimated using quality control 
samples in plasma using three replicates. The limit of quantification was estimated using three 
replicates and was defined as the lowest concentration associated with a tenfold signal:noise ratio. 
The limit of detection was estimated using three replicates and was defined as the concentration 
at which signal:noise was at least three fold. 
Component analysis of injectable formulation 
A component analysis was determined by calculating the ratios of the three peak areas 
representing gentamicin C1a, C2, and C1 in the HPLC chromatograms. The component analysis 
was confirmed by proton NMR spectrum of the commercial injectable formulation of gentamicin 
(Gentamicin sulfate; Sparhawk Laboratories, Lenexa, Kansas, USA)  from the same 
manufacturing lot that was administered to the horses. A 1 mg/mL in 99% D2O gentamicin 
solution was made from the injectable solution, and 5 µL of a DSS solution in D2O (3mM) was 
added, giving a final concentration of 0.03 mM of DSS. The proton NMR spectrum using a one-
pulse sequence with water presaturation and 1024 scans was taken of the 1 mg/mL solution at 600 
MHz. Peak assignments were made using the purpurosamine anomeric protons that are close to 6 
ppm, and resonances were based on previous assignments (Deubner et al., 2003). The component 
analysis was compared to the requirements for the manufacturing of gentamicin published by the 
US Pharmacopoeia (Vydrin et al., 2003). This analysis was used to determine the dose of each 
gentamicin component that was administered to each horse and was used for pharmacokinetic 
determinations for each component. 
Pharmacokinetic analysis 
Plasma gentamicin component concentrations following the intravenous administration of 
gentamicin were analyzed compartmentally using Thermo Kinetica™ software version 5.0 
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(Thermo Fisher Scientific, Philadelphia, Pennsylvania, USA). Intravenous data for each horse 
were fit to the following equation: 
 
Data were weighted by the reciprocal of the plasma gentamicin concentration and were fit to 
standard compartmental models. The most appropriate model was selected using Aikaike’s 
information criterion and the Schwarz criterion, and standard compartmental equations were then 
used to estimate the pharmacokinetic parameters for each horse. The mean and standard deviation 
for each group (Miniature Horses and Quarter Horses) was estimated for each pharmacokinetic 
parameter.  
Allometric comparisons 
The total body clearance for the three gentamicin components determined in Miniature Horses 
was compared to that predicted by standard allometry, as has been reported previously (Mordenti, 
1986). The general form of the allometric equation used for scaling of pharmacokinetic 
parameters was: 
y = a ⋅ BWb, 
where y is gentamicin clearance; BW is the body weight;  a is the allometric coefficient, and b is 
the allometric exponent. The allometrically predicted gentamicin clearance in Miniature Horses 
was calculated from the Quarter Horse clearance data by solving for the mass coefficient in the 
equation above and setting b = 0.75, as is frequently used in standard allometric calculations and 
is arguably a universal scaling exponent across species (Hu & Hayton, 2001). The values of log10 
total body clearance were regressed against log10 body weight and compared to the curve 
predicted by standard allometry. 
C = Ai ⋅e−α⋅t
i=1
n
∑
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Statistical analysis 
A Wilcoxon rank-sum test was used to analyze the difference in body condition score between 
the groups, whereas a two-sample t-test was used to test whether age differed between Quarter 
Horses and Miniature Horses. Two sample Student’s t tests were used to test the difference in 
selected pharmacokinetic parameters: mass normalized clearance (Cl), elimination phase rate 
constant (γ), area under the plasma concentration versus time curve (AUC), apparent volume of 
distribution at steady state (Vdss), and volume of the central compartment (Vc). Significance was 
set at α = 0.05. Statistical calculations were performed using SigmaPlot™ software version 11.0 
(Systat Software, Inc., Chicago, Illinois, USA). 
 
Results: 
Therapeutic drug monitoring survey 
The email-based survey was sent to representatives of each of the 33 veterinary teaching hospitals 
in the United States and Canada. Twenty-six (79%) of the institutions contacted responded to the 
questionnaire (Table 4). Less than one-half of the 26 respondents indicated that TDM of 
aminoglycosides is performed currently by their hospital, and a smaller minority (15 %) of the 
respondents indicated that TDM is performed in house at their hospital. The majority of TDM 
performed by respondents is for equine patients and uses an antibody-based assay (For complete 
results, see Appendix B). 
Table 4. Summary of survey data for therapeutic drug monitoring survey.  
  Frequency 
(Percentage) 
 Annual samples performed 
(average #) 
Response rate 26/33 (79%)   
TDM performed 11/26 (42%)  3.9 
TDM performed in house 4/26 (15%)  5.8 
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HPLC Assay 
At fortified plasma gentamicin component concentrations of 1.5 µg·mL-1, 3.5 µg·mL-1, and 17.5 
µg·mL-1, recovery of gentamicin was 55 ± 8%, 57 ± 14%, and 54 ± 13%, respectively, for 
gentamicin component C1a, 56 ± 10%, 57 ± 19%, and 56 ± 14%, respectively, for gentamicin 
component C2, and 63 ± 12%, 66 ± 12%, and 58 ± 14%, respectively, for gentamicin component 
C1. At a plasma concentration of 10 µg·mL-1, recovery of tobramycin was 68 ± 17%. Intraday 
accuracy of the assay at 1.5 µg·mL-1, 3.5 µg·mL-1 and 17.5 µg·mL-1 was 94%, 98%, and 100%, 
respectively, for gentamicin component C1a, 97%, 98%, and 99%, respectively, for gentamicin 
component C2, and 100%, 98%, and 98%, respectively, for gentamicin component C1. Intraday 
coefficient of variation at 1.5 µg·mL-1, 3.5 µg·mL-1, and 17.5 µg·mL-1 was 1%, 3%, and 2%, 
respectively, for gentamicin component C1a, 2%, 1%, and 2%, respectively, for gentamicin 
component C2, and 1%, 1%, and 3%, respectively, for gentamicin component C1. Interday 
accuracy at 1.5 µg·mL-1, 3.5 µg·mL-1 and 17.5 µg·mL-1 was 97%, 98%, and 98%, respectively, 
for gentamicin component C1a, 99%, 98%, and 98%, respectively, for gentamicin component C2, 
and 96%, 97%, and 97%, respectively, for gentamicin component C1. Interday coefficient of 
variation at 1.5 µg·mL-1, 3.5 µg·mL-1, and 17.5 µg·mL-1 was 1%, 4%, and 3%, respectively, for 
gentamicin component C1a, 1%, 3%, and 3%, respectively, for gentamicin component C2, and 
2%, 4%, and 4%, respectively, for gentamicin component C1. The limit of quantification was 0.2 
µg·mL-1 for gentamicin components C1a and C2 and was 0.1 µg·mL-1 for gentamicin component 
C1. The LOQ of the three components was associated with good accuracy and precision, with an 
accuracy of 95%, 94%, and 94%, for C1a, C2, and C1 respectively, and a coefficient of variation 
of 5%, 4%, and 8%, respectively. The limit of detection was 0.05 µg·mL-1 for each gentamicin 
component. 
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Component analysis of injectable formulation 
Proton NMR determined that the injectable gentamicin used in the study was composed of 22% 
component C1a, 30% component C2, 32% component C1, and 16% component C2a. Ratio 
calculations of peak area from the HPLC chromatograms in the study determined that the 
percentages of the three components detected were 24% C1a, 26% C2, and 50% C1.  
Quantification of gentamicin 
All horses tolerated the administration of a single dose of gentamicin well, with no adverse 
effects noted for the duration of the study.  Gentamicin concentrations were rapidly distributed 
after intravenous administration, followed by a slower distributive phase and an elimination 
phase. Gentamicin components C1a, C2, and C1 could be quantified for at least 12 hours in all 
horses and gentamicin component C1 could be quantified for 24 hours in 7/8 Quarter Horses and 
8/8 Miniature Horses (Figure 4).  
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Figure 4: Mean (± s.e.m.) plasma concentrations of gentamicin components a) C1a b) C2 c) C1 
and d) summed gentamicin components C1a, C2, and C1 after i.v. administration of gentamicin at 
a dose rate of 6.6 mg/kg to eight Miniature Horses and eight Quarter Horses. Gentamicin 
component concentrations were similar between the two groups throughout the sampling period. 
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Pharmacokinetics 
The most appropriate compartmental model for pharmacokinetic analysis was determined to be a 
three compartment model (Table 5). There were no significant differences in the pharmacokinetic 
parameters of gentamicin components C1a, C2, C1, or the summed gentamicin components 
between breed groups in total body clearance (P = 0.18, 0.23, 0.20, 0.20 respectively), 
elimination phase rate constant (P = 0.37, 0.51, 0.96, 0.37 respectively), AUC (P = 0.19, 0.26, 
0.21, 0.21 respectively), or the Vc (P = 0.99, 0.93, 0.98, 0.93 respectively). In addition, the mass 
specific clearance of gentamicin was not related to body weight (Figure 5a).  
Table 5a. Comparison of pharmacokinetic parameters after i.v. administration of gentamicin to 
Quarter Horses and Miniature Horses. a) gentamicin component C1a 
Parameter Quarter Horses Miniature Horses 
Dose (mg·kg bwt-1) 1.58 ± 0.01 (1.57-1.59) 1.57 ± 0.01 (1.55-1.59) 
C0 (µg·mL-1) 43.1 ± 14.5 (30.6-70.9) 41.7 ± 10.2 (31.2-58.2) 
A (µg·mL-1) 23.5 ± 14.0 (10.5-51.9) 22.8 ± 7.6 (16.5-37.5) 
B (µg·mL-1) 14.0 ± 3.1 (8.8-18.4) 12.6 ± 2.2 (9.7-15.4) 
C (µg·mL-1) 5.5 ± 2.9 (0.6-10.0) 6.3 ± 3.3 (3.2-12.7) 
t1/2α (h)* 0.06 ± 0.02 (0.03-0.09) 0.06 ± 0.02 (0.04-0.08) 
t1/2β (h)* 0.82 ± 0.18 (0.54-1.66) 0.60 ± 0.33 (0.30-1.14) 
t1/2γ (h)* 3.27 ± 0.38 (2.52-20.14) 2.87 ± 0.62 (2.22-3.87) 
t1/2k10 (h)* 0.74 ± 0.15 (0.49-0.96) 0.64 ± 0.22 (0.43-0.96) 
k10 (hr-1) 0.94 ± 0.23 (0.75-1.41) 1.08 ± 0.34 (0.72-1.61) 
k12 (hr-1) 0.40 ± 0.25 (0.22-0.96) 0.72 ± 0.61 (0.23-1.95) 
k21 (hr-1) 0.40 ± 0.20 (0.05-0.68) 0.54 ± 0.31 (0.29-1.10) 
k13 (hr-1) 5.89 ± 4.46 (2.20-15.63) 5.42 ± 1.92 (3.31-8.07) 
k31 (hr-1) 5.88 ± 0.85 (4.58-6.49) 6.16 ± 1.85 (4.45-9.32) 
35	  
	  
Vc (L·kg bwt-1) 0.040 ± 0.010 (0.022-0.052) 0.040 ± 0.009 (0.027-0.050) 
Vd(ss) (L·kg bwt-1) 0.123 ± 0.046 (0.096-0.236) 0.120 ± 0.020 (0.093-0.149) 
Vd(area) (L·kg bwt-1) 0.231 ± 0.208 (0.125-0.742) 0.175 ± 0.047 (0.106-0.236) 
Cl (mL·min-1·kg bwt-1) 0.59 ± 0.10 (0.43-0.74) 0.68 ± 0.15 (0.52-0.99) 
AUC (µg·h·mL-1) 45.6 ± 8.3 (35.3-62.4) 40.0 ± 8.1 (26.8-51.1) 
MRT (hr) 3.7 ± 2.2 (2.7-9.2) 3.0 ± 0.5 (2.4-3.7) 
 
Table 5b. Comparison of pharmacokinetic parameters after i.v. administration of gentamicin to 
Quarter Horses and Miniature Horses. b) gentamicin component C2 
Parameter Quarter Horses Miniature Horses 
Dose (mg·kg bwt-1) 1.75 ± 0.01 (1.73-1.76) 1.74 ± 0.02 (1.72-1.76) 
C0 (µg·mL-1) 46.9 ± 16.2 (33.3-77.2) 45.9 ± 11.6 (32.8-63.6) 
A (µg·mL-1) 25.8 ± 15.5 (11.9-56.7) 25.2 ± 8.7 (16.8-41.1) 
B (µg·mL-1) 15.1 ± 3.6 (9.4-20.0) 13.8 ± 3.1 (8.5-17.6) 
C (µg·mL-1) 6.0 ± 3.6 (0.6-11.5) 7.0 ± 4.2 (3.0-14.2) 
t1/2α (h)* 0.06 ± 0.02 (0.03-0.09) 0.05 ± 0.01 (0.04-0.10) 
t1/2β (h)* 0.80 ± 0.20 (0.46-1.70) 0.58 ± 0.29 (0.31-1.38) 
t1/2γ (h)* 3.22 ± 0.46 (2.38-13.69) 2.92 ± 0.72 (2.23-5.04) 
t1/2k10 (h)* 0.72 ± 0.16 (0.47-0.95) 0.63 ± 0.24 (0.42-1.03) 
k10 (hr-1) 0.96 ± 0.26 (0.73-1.46) 1.09 ± 0.36 (0.67-1.63) 
k12 (hr-1) 0.41 ± 0.34 (0.20-1.20) 0.76 ± 0.61 (0.33-2.04) 
k21 (hr-1) 0.42 ± 0.23 (0.06-0.75) 0.55 ± 0.31 (0.20-1.11) 
k13 (hr-1) 5.82 ± 4.54 (2.40-15.66) 5.51 ± 1.84 (2.91-8.10) 
k31 (hr-1) 5.77 ± 1.02 (4.34-7.51) 6.27 ± 1.72 (3.53-9.19) 
Vc (L·kg bwt-1) 0.040 ± 0.012 (0.023-0.053) 0.040 ± 0.009 (0.027-0.053) 
Vd(ss) (L·kg bwt-1) 0.114 ± 0.017 (0.098-0.153) 0.124 ± 0.021 (0.094-0.152) 
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Vd(area) (L·kg bwt-1) 0.211 ± 0.144 (0.123-0.559) 0.184 ± 0.053 (0.107-0.240) 
Cl (mL·min-1·kg bwt-1) 0.61 ± 0.09 (0.47-0.76) 0.69 ± 0.16 (0.52-1.01) 
AUC (µg·h·mL-1) 48.6 ± 7.6 (38.0-62.3) 43.7 ± 9.1 (29.1-56.0) 
MRT (hr) 3.2 ± 0.9 (2.6-5.4) 3.0 ± 0.5 (2.4-4.1) 
 
Table 5c. Comparison of pharmacokinetic parameters after i.v. administration of gentamicin to 
Quarter Horses and Miniature Horses. c) gentamicin component C1 
Parameter Quarter Horses Miniature Horses 
Dose (mg·kg bwt-1) 3.30 ± 0.02 (3.27-3.33) 3.29 ± 0.03 (3.25-3.32) 
C0 (µg·mL-1) 86.9 ± 30.3 (58.2-145.8) 86.6 ± 30.6 (62.1-148.2) 
A (µg·mL-1) 48.1 ± 28.6 (20.5-107.0) 50.1 ± 22.8 (30.5-93.5) 
B (µg·mL-1) 29.8 ± 5.5 (19.3-37.4) 28.4 ± 5.6 (21.5-37.7) 
C (µg·mL-1) 9.0 ± 5.8 (1.3-18.0) 8.2 ± 6.0 (0.7-17.2) 
t1/2α (h)* 0.06 ± 0.02 (0.03-0.13) 0.06 ± 0.02 (0.02-0.09) 
t1/2β (h)* 0.91 ± 0.31 (0.56-1.69) 0.73 ± 0.37 (0.29-1.88) 
t1/2γ (h)* 3.42 ± 0.90 (2.57-9.63) 3.44 ± 1.44 (2.20-9.59) 
t1/2k10 (h)* 0.72 ± 0.21 (0.51-1.04) 0.61 ± 0.26 (0.34-1.02) 
k10 (hr-1) 0.96 ± 0.26 (0.67-1.35) 1.14 ± 0.49 (0.68-1.35) 
k12 (hr-1) 0.32 ± 0.26 (0.13-0.90) 0.61 ± 0.82 (0.06-2.54) 
k21 (hr-1) 0.34 ± 0.17 (0.08-0.60) 0.37 ± 0.26 (0.08-0.92) 
k13 (hr-1) 5.68 ± 4.41 (1.37-15.38) 5.84 ± 4.24 (3.00-15.67) 
k31 (hr-1) 5.47 ± 1.43 (3.03-7.08) 5.64 ± 2.94 (3.31-12.63) 
Vc (L·kg bwt-1) 0.041 ± 0.012 (0.023-0.057) 0.041 ± 0.011 (0.022-0.052) 
Vd(ss) (L·kg bwt-1) 0.112 ± 0.011 (0.094-0.124) 0.127 ± 0.012 (0.100-0.156) 
Vd(area) (L·kg bwt-1) 0.209 ± 0.089 (0.134-0.403) 0.246 ± 0.105 (0.129-0.459) 
Cl (mL·min-1·kg bwt-1) 0.62 ± 0.10 (0.48-0.79) 0.72 ± 0.17 (0.53-1.06) 
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AUC (µg·h·mL-1) 90.1 ± 14.2 (68.6-114.6) 79.8 ± 17.3 (52.0-103.2) 
MRT (hr) 3.1 ± 0.6 (2.3-4.2) 3.0 ± 0.6 (2.1-3.7) 
 
Table 5d. Comparison of pharmacokinetic parameters after i.v. administration of gentamicin to 
Quarter Horses and Miniature Horses. d) gentamicin components C1a, C2, and C1 summed 
Parameter Quarter Horses Miniature Horses 
Dose (mg·kg bwt-1) 6.62 ± 0.04 (6.57-6.68) 6.60 ± 0.06 (6.52-6.67) 
C0 (µg·mL-1) 176.7 ± 60.3 (122.7-292.2) 174.7 ± 50.0 (127.4-259.3) 
A (µg·mL-1) 96.5 ± 58.0 (41.0-214.0) 96.5 ± 37.1 (64.9-155.7) 
B (µg·mL-1) 57.8 ± 11.8 (37.4-73.3) 51.3 ± 13.6 (41.0-72.1) 
C (µg·mL-1) 22.4 ± 10.9 (4.9-39.9) 26.8 ± 15.1 (12.2-54.2) 
t1/2α (h)* 0.06 ± 0.02 (0.03-0.10) 0.05 ± 0.02 (0.03-0.09) 
t1/2β (h)* 0.84 ± 0.20 (0.53-1.64) 0.58 ± 0.30 (0.29-1.11) 
t1/2γ (h)* 3.07 ± 0.13 (2.51-5.82) 2.80 ± 0.72 (2.21-3.53) 
t1/2k10 (h)* 0.72 ± 0.19 (0.50-0.97) 0.62 ± 0.22 (0.39-0.99) 
k10 (hr-1) 0.97 ± 0.26 (0.71-1.39) 1.12 ± 0.40 (0.70-1.76) 
k12 (hr-1) 0.36 ± 0.28 (0.14-0.99) 0.75 ± 0.69 (0.23-2.27) 
k21 (hr-1) 0.40 ± 0.16 (0.14-0.64) 0.57 ± 0.33 (0.28-1.21) 
k13 (hr-1) 5.74 ± 4.39 (1.91-15.39) 5.65 ± 2.76 (3.29-11.49) 
k31 (hr-1) 5.74 ± 0.87 (4.36-7.01) 6.23 ± 2.23 (4.40-11.35) 
Vc (L·kg bwt-1) 0.041 ± 0.011 (0.023-0.054) 0.040 ± 0.010 (0.026-0.051) 
Vd(ss) (L·kg bwt-1) 0.107 ± 0.008 (0.095-0.148) 0.120 ± 0.019 (0.095-0.148) 
Vd(area) (L·kg bwt-1) 0.171 ± 0.039 (0.128-0.250) 0.177 ± 0.039 (0.107-0.238) 
Cl (mL·min-1·kg bwt-1) 0.62 ± 0.09 (0.50-0.77) 0.71 ± 0.16 (0.53-1.03) 
AUC (µg·h·mL-1) 182.0 ± 26.2 (141.9-224.3) 162.4 ± 33.7 (108.0-210.0) 
MRT (hr) 2.9 ± 0.3 (2.5-3.4) 2.9 ± 0.4 (2.3-3.5) 
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Values are expressed as mean or *harmonic mean ± s.d. (range)[37]. Dose = dose administered; 
C0 = serum drug concentration at time 0; A = coefficient of rapid distribution phase; B = coefficient 
of slow distribution phase; C = coefficient of elimination phase; t1/2α = rapid distributional half-life; 
t1/2β= slow distributional half-life; t1/2γ = terminal elimination phase half-life; t1/2k10 = elimination 
half-life; k
10
 = first-order rate constant for elimination from the central compartment; other 
intercompartmental rate constants follow similar nomenclature; Vc = apparent volume of the 
central compartment; Vd(ss) = apparent volume of distribution at steady state; Vd(area) = apparent 
volume of distribution by area; Cl = total body clearance; AUC = Area under the plasma 
concentration versus time curve, extrapolated to infinity; MRT = mean residence time 
 
Allometric comparison 
The regression curve relating measured total body clearance of summed gentamicin to body 
weight (Figure 5b) was associated with a mass exponent of 0.91: 
 CL = 0.064 ⋅ BW0.91, R2 = 0.94 
If the clearance of gentamicin in Miniature Horses had varied allometrically from that of Quarter 
Horses by the ¾ mass exponent, then the predicted gentamicin clearance in the Miniature Horses 
would have been 0.90 mL·min-1·kg bwt-1, more than 25% greater than the measured clearance of 
0.71 mL·min-1·kg bwt-1. The statistical power (β) of the present study to detect such a difference 
was 0.97, with s.d. = 0.14 and α = 0.05. The other pharmacokinetic parameters tested were 
similarly unrelated to body weight (elimination rate and AUC) or were directly proportional to 
body weight (Vdss, Vc; data not shown). 
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Figure 5b: Relationship between summed gentamicin clearance and body weight. a) Mass 
specific clearance of summed gentamicin versus body weight in Miniature Horses and Quarter 
Horses, demonstrating that total body clearance was similar between the two groups when 
normalized to body weight. b) Total body clearance of gentamicin versus body weight in 
Miniature Horses and Quarter Horses, showing that total body clearance varied proportionally 
with body weight. The regression line calculated from the data (solid line) is compared to that 
predicted from standard allometry (dashed line). 
 
Discussion: 
Therapeutic drug monitoring of aminoglycosides is performed rarely in veterinary teaching 
hospitals in the United States and Canada. The few hospitals that do have the capability to 
perform TDM in house analyze very few samples annually using an antibody-based assay, with 
the vast majority of samples being from horses. The emphasis on TDM of aminoglycosides in 
horses is consistent with the recommendation in the literature that therapeutic drug monitoring be 
performed routinely even in healthy foals to ensure that the desired peak and trough 
concentrations are being achieved, especially due to the inherent individual variation in the 
pharmacokinetic parameters of gentamicin (Burton et al., 2012). However, the infrequent 
performance of TDM in veterinary medicine is not consistent with the importance of this 
technique as demonstrated in human studies (van Lent-Evers et al., 1999; Rea et al., 2008). A 
retrospective study in humans demonstrated that the majority of medical intensive care unit 
patients would not be predicted to achieve a pharmacodynamic target based on minimum 
inhibitory concentrations (Rea et al., 2008), emphasizing the potential effect of TDM in this 
population. A multicenter prospective study in humans compared an ‘active’ TDM strategy using 
pharmacokinetic dosage optimization, subsequent adaptive control, and ongoing patient follow-
up with a ‘standard’ TDM strategy using attending physician dosing and TDM on request only, 
and showed shorter hospitalization times, reduced nephrotoxicity, reduced mortality in patients 
admitted with an infection, and lower total costs with the ‘active’ TDM strategy (van Lent-Evers 
et al., 1999). In the equine species, a study that measured serum gentamicin concentrations in 
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equine patients considered at high-risk for developing toxicosis found that nine of the twelve 
horses studied required dosage adjustment to optimize therapeutic concentrations (Sojka and 
Brown, 1986). The reason for the current infrequent performance of TDM in veterinary medicine 
is unclear, but it is likely that it is correlated with the low availability of the test and the expense 
associated currently with the fluorescent polarization immunoassay. 
The present study employed an improved high performance liquid chromatography method that 
allowed the sensitive and specific determination of the concentrations of the three main 
gentamicin components in equine plasma. The sensitivity of the method was slightly improved as 
compared to the previously reported HPLC method, with the limits of quantification of the 
components of 0.2 µg·mL-1 (C1a and C2) the same the previous report, and 0.1 µg·mL-1 (C1) 
lower than the previous report of 0.4 µg·mL-1 (C1) (Steinman et al., 2002). The stated accuracy, 
precision, and recovery of the novel assay were all within acceptable limits. The use of a two 
compartment model describing gentamicin pharmacokinetics in horses predominates in the 
literature (Jones et al., 1998; Magdesian et al., 1998; Martin-Jimenez et al., 1998), but the 
increased sensitivity of the assay in the present study with a limit of detection of 0.05 µg·mL-1 
compared to the limit of detection of 0.16 µg·mL-1  noted in previous work (Jones et al., 1998) 
allowed the definition of a third compartment. The articles of the US Pharmacopoeia stipulate the 
following limits for the component composition of gentamicin: C1a, 10-35%, C2, 25-55%, and 
C1, 25-50% (Vydrin et al., 2003). The proportions obtained in the present study using the HPLC 
method were 24% C1a, 26% C2, and 50% C1. In contrast, the proportions obtained in the present 
study using the NMR analysis appeared to be similar at 22% C1a, 30% C2, 32% C1, and 16% 
C2a. The authors hypothesize that the HPLC peak identified as C1 was actually a combination of 
components C1 and C2a, which would then be the sum of these components on NMR 
analysis,48%, which was very similar to the 50% composition determined for C1 by HPLC. 
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Therefore, all the percentages obtained via HPLC were within 14% of the percentages obtained 
via NMR, and were within the limits specified by the US Pharmacopoeia. 
The values calculated for clearance for the horses in the present study were lower than those 
reported previously for gentamicin components in light-breed horses (Steinman et al., 2002). 
Specifically, the mean mass specific clearance of gentamicin components C1a, C2, and C1 for all 
horses in the present study of 0.64, 0.65, and 0.67 mL·min-1·kg bwt-1 , respectively, were lower 
than the clearance for gentamicin components C1a, C2, and C1 of 1.63, 1.10, and 1.03 mL·min-
1·kg bwt-1 respectively reported previously in light-breed horses given the same dose of 
gentamicin (Steinman et al., 2002). Additionally, the reported AUC values for Quarter Horses in 
present study were higher, and the Vc values for Quarter Horses in the present study were lower 
than those reported previously (Steinman et al., 2002). The design of the present study allowed 
better definition of the initial distributive phase via sampling at 3 minutes and 6 minutes after 
gentamicin administration, instead of taking the first sample at 10 minutes as did the previous 
study (Steinman et al., 2002). Since the lower limit of quantification of the present study also 
allowed quantification of all three gentamicin components for a longer duration after 
administration, it is hypothesized that these differences in measured clearance, AUC, and Vc are 
due to the improved definition of all three compartments of gentamicin modeling in the present 
study..The clearance of gentamcin for the horses in the present study was also lower than that of 
approximately 1.04 mL·min-1·kg determined commonly in studies using fluorescence polarization 
immunoasay bwt-1 (Jones et al., 1998). Comparisons with studies that utilize this method of 
analysis are difficult since the gentamicin components are not analyzed separately with this 
method, and it is likely that the individual component analysis and low limit of quanitification of 
the present study allowed a more precise definition of clearance. 
The hypothesis of the present study that gentamicin would follow an allometric relationship in the 
horse was based on the large variation in body size between Miniature Horses and Quarter 
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Horses. The efficacy of gentamicin is well correlated to its plasma concentration, and it is 
primarily eliminated in an unchanged form via glomerular filtration, characteristics which make it 
one of a number of drugs that have been reported to scale allometrically between species (Riviere 
et al., 1997). Indeed, the elimination half-life of gentamicin correlates with body weight with a 
coefficient of determination of 0.86 in comparisons between a range of animal species and was 
therefore expected to scale allometrically within a species. However, allometric scaling of the 
pharmacokinetic parameters of gentamicin was not demonstrated within horses in the present 
study. Comparisons between clinically relevant pharmacokinetic parameters that have been 
previously shown to scale allometrically with body weight (Cox et al., 2004; Dinev, 2008; Gebru 
et al., 2011) did not show a significant difference between the horse breeds employed in the 
current study.  To determine if there was sufficient range in body weight and statistical power in 
the present study to reveal a standard allometric relationship in which drug clearance varies with 
body weight raised to the ¾ power, the predicted gentamicin clearance for Miniature Horses 
using standard allometry was compared with the actual measured total body clearance for the 
summed gentamicin components (Figure 5). As the power of the present study to show this 
relationship was high at 0.97, it can be confidently stated that gentamicin does not follow 
standard allometry in Miniature Horses as compared to Quarter Horses. This result is similar to 
the only other study comparing the pharmacokinetics of Miniature Horses to Quarter Horses, in 
which flunixin was demonstrated to be without any allometric effect in these breeds (Lee & 
Maxwell, in press). The clearance of gentamicin was also plotted against body weight on a double 
log10 plot to examine the possibility of a nonproportional relationship following a scaling factor 
other than standard allometry, such as the 2/3 power commonly used in body surface area 
calculations (Gouma et al., 2012). The mass exponent of this regression was 0.91 and did not 
significantly differ from unity (P>0.05). Although clearance was approximately proportional to 
body weight, the mass exponent value less than unity does suggest that a weak allometric 
relationship between gentamicin clearance and body weight may be present within horses. 
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However, if such an allometric relationship is truly present it is weak and unlikely to be of 
clinical significance in dose determinations for gentamicin in Miniature Horses.  
The efficacy and toxicity of gentamicin have not been compared between breeds in the horse. 
However, it has been demonstrated that pharmacokinetic/pharmacodynamic indices for 
antibiotics such as gentamicin in humans vary greatly with different patient ages and with 
reduction in clearance (Nielsen et al., 2011). Since the efficacy and toxicity of gentamicin in 
patient populations can primarily be explained by disease factors that impact pharmacokinetic 
parameters, dosage recommendation for gentamicin administration to Miniature Horses can 
primarily rely upon their pharmacokinetic similarity to Quarter Horses. 
The results of the present study do not support a need to adjust the dose rate of gentamicin for 
Miniature Horses. As neither gentamicin nor flunixin disposition depended upon body weight 
when comparing Miniature Horses to a common light-breed of horses, it is likely that allometric 
effects need not be taken into account when designing dosing regimens for Miniature Horses. 
Veterinarians may therefore confidently administer gentamicin and other drugs to Miniature 
Horses using typical equine dosing regimens. However, TDM is recommended as part of the 
treatment protocol for the administration of aminoglycosides in both human and veterinary 
medicine (Burton et al., 2012; Sojka and Brown, 1986), and the administration of gentamicin to 
Miniature Horses is no exception.  
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CHAPTER IV 
 
 
CONCLUSION 
 
The large variation in body size within the equine species led to the hypotheses that intraspecific 
allometric scaling plays a role in the disposition of several important therapeutics of the horse, 
and that flunixin and gentamicin would scale allometrically with body weight in the horse. 
However, the results of the present study do not support pharmacokinetic scaling of either drug in 
the horse. Statistical comparisons between Miniature Horses and Quarter Horses were performed 
on those pharmacokinetic parameters used commonly in allometric calculations and deemed 
clinically relevant to dose calculations (Cox et al., 2004; Dinev, 2008; Gebru et al., 2011). These 
key pharmacokinetic parameters showed no significant differences between Miniature Horses and 
Quarter Horses for either drug. When the measured clearance for each drug in Miniature Horses 
was plotted against body weight on a double log10 plot, the mass exponent of each comparison 
was similar to unity, further demonstrating the absence of a clinically relevant allometric effect. 
There could be several reasons for the inability of the present study to demonstrate a clinically 
relevant allometric effect in the horse. Although the inclusion of draft horses in the study would 
have allowed comparison across a full order of magnitude in body weight, instead of the ½ order 
of magnitude present between Miniature Horses and Quarter Horses, it is unlikely that Miniature 
Horses follow standard allometry, as the study was adequately powered to detect such a 
difference between the breeds utilized. It is possible, however, that a weak allometric effect may 
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have been demonstrated by inclusion of horses over a wider range in body weights and with a 
larger number of horses.. There are several possible explanations for the lack of pharmacokinetic 
scaling reported in the present studies on flunixin and gentamicin disposition in Miniature Horses. 
First, the equine species demonstrates a smaller range in body weights than does the dog, in 
which intraspecific allometry in drug disposition has been demonstrated (Satyanarayana Achanta, 
personal communication). There is also a much smaller span in orders of magnitude within body 
weight in the equine species than is commonly investigated in interspecific comparisons, many of 
which span the eight orders of magnitude present in mammals (Savage et al., 2008). This smaller 
span in orders of magnitude within body weight may hinder demonstration of an allometric effect 
because it is difficult to detect a statistical difference between unity and the standard allometric 
exponent across a narrower range. The only previous paper to demonstrate an allometric effect in 
equids compared clearance of phenylbutazone in miniature donkeys to previously reported 
clearance in standard donkeys (Matthews et al., 2001). While this study may be overly reliant on 
previously reported data, it is also possible that the metabolism of phenylbutazone in donkeys is 
different from that in horses, or that phenylbutazone is more prone to exhibit allometric scaling 
than is flunixin. Finally, it is possible that there are breed effects within the equine species that 
supersede the influence of allometric relationships in both physiology and pharmacokinetics. This 
could have an effect on the ability of the Quarter Horses in the present study to be representative 
of all light-breed horses, and could have an effect on the uniformity of pharmacokinetics within 
the Miniature Horse breed since it is the result of the selective breeding of various light horse 
breeds. Further studies investigating allometry in horses may include the comparison of the 
clearance of gentamicin in Miniature Horses and draft horses, the comparison of the clearance of 
phenylbutazone in Miniature Horses and Quarter Horses, and the comparison of the glomerular 
filtration rates of Miniature Horses, Quarter Horses, and other light and draft breeds of horses. 
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Novel high performance liquid chromatography methods were employed in the present study for 
the determination of the concentration of flunixin meglumin and gentamicin in equine plasma. 
The sensitivities of the methods used in the present study were improved as compared to 
previously reported methods (Soma et al., 1988; Steinman et al., 2002). The improved sensitivity 
of the method for flunixin analysis allowed the reliable quantification of flunixin for up to 24 
hours after administration for the first time, which demonstrated the presence of a third 
compartment as compared to previous studies that described a two compartment model (Chay et 
al., 1982; Semrad et al., 1985; Lees et al., 1987; Soma et al., 1988). The sensitivity of the method 
for gentamicin analysis with the individual analysis of the three main components of gentamicin 
also allowed the demonstration of a third compartment as compared to the two compartment 
model described previously in the literature (Magdesian et al., 1998; Martin-Jimenez et al., 1998). 
Both methods described in the present study were deemed robust and feasible for use in future 
pharmacokinetic studies. 
Although active therapeutic drug monitoring strategies for aminoglycosides have been 
demonstrated to allow shorter hospitalization times, reduced nephrotoxicity, reduced mortality in 
patients admitted with an infection, and lower total costs in human medicine (van Lent-Evers et 
al., 1999), therapeutic drug monitoring is presently performed infrequently in veterinary teaching 
hospitals in the United States and Canada. The few veterinary teaching hospitals that do have the 
capability to perform TDM within their institution analyze very few samples annually using an 
antibody-based assay, with the vast majority of samples being from equine patients. The reason 
for the infrequent performance of TDM in veterinary medicine is unclear, but it is likely that it is 
correlated with the low availability of the test in currently used clinical analyzers and the expense 
associated with currently available assays. Dosage recommendations for gentamicin should 
include a recommendation for TDM in all horses, including Miniature Horses. 
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Prior to this investigation, the absence of objective studies exploring the pharmacokinetics of any 
veterinary drug in the Miniature Horse has required the veterinary practitioner to rely on 
subjective information to support any therapeutic decisions in this breed. Although it remains 
imperative to adjust the drug dose to body weight when administering any therapeutic to a 
Miniature Horse, the results of the present study allow veterinarians to confidently administer 
both flunixin meglumine and gentamicin to Miniature Horses using typical equine dosing 
regimens. Since elimination half-life is significantly correlated with body weight in drugs such as 
gentamicin that are cleared via glomerular filtration (Riviere et al., 1997), the absence of a 
significant allometric effect of body weight on drug disposition makes it unlikely that 
pharmacokinetic scaling is clinically important within the equine species. Therefore, there is now 
objective evidence to support the use of typical equine dosing regimens for therapeutics in the 
Miniature Horse.
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APPENDICES 
 
 
 
APPENDIX A – Therapeutic Drug Monitoring Survey 
 
1) To your knowledge, does your hospital perform therapeutic drug monitoring of gentamicin, 
amikacin, or other aminoglycosides? If your answer to this question is "No", the remaining 
questions are not applicable. Please email the survey results to Dr. Lee, as described below. 
2) Is the assay performed in house or off site? If the assay is performed off site, please specify 
where it is performed. 
3) What assay and instrument is used? 
4) Approximately how many samples are analyzed per year? 
5) Approximately what proportion of samples is from small animal patients as compared to large 
animal patients? 
6) If you have any further information to share about patient demographics (age or species most 
commonly subjected to TDM of aminoglycosides), please elaborate
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APPENDIX B – Therapeutic Drug Monitoring Survey Results 
	   	   	   	   	   	   	   Response? 
Perform 
TDM? 
In house/off 
site Assay #samples/year type  of patient 
Auburn X Yes in house Seimens Xpand 
2012: 15 
amikacin, 0 
gentamicin; 2011: 
1 amikacin, 1 
gentamicin; 2010: 
15 amikacin, 3 
gentamicin 
75% small animal 
for amikacin, 
majority of 
gentamicin is large 
animal  
Colorado State X Yes in house unknown few majority equine 
Cornell X No     
Iowa       
Kansas State X No     
Louisiana State X No     
Michigan State       
Mississippi State X No     
North Carolina 
State X No     
Oklahoma State X No     
Oregon State X No     
Purdue X Yes off site  3.4 99% horses 
Texas A&M X Yes off site  0-1 horses 
Ohio State X Yes off site unknown unknown unknown 
Tufts X No     
Tuskegee       
California, Davis       
Florida X Yes off site unknown 10 to 15 horses 
Georgia       
Illinois X Yes in house Immunolite 2000 0 
predict would be 
foals 
Minnesota       
Missouri X Yes off site  2 foals 
Penn       
Tennessee X No     
Wisconsin X No     
Virginia X No     
Washington State X No     
Western University X No     
Calgary X No     
Guelph X No     
Montreal X Yes in house unknown unknown unknown 
Atlantic X Yes off site  1 to 2 
95% horses, 
usually foals, 5% 
small animal 
Saskatchewan X Yes off site   1 horses 
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